354 related articles for article (PubMed ID: 27597420)
1. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
2. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
McGinnis LM; Nybakken G; Ma L; Arber DA
Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
[TBL] [Abstract][Full Text] [Related]
3. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
5. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
7. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract][Full Text] [Related]
8. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
9. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
[TBL] [Abstract][Full Text] [Related]
12. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
[TBL] [Abstract][Full Text] [Related]
13. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
[TBL] [Abstract][Full Text] [Related]
14.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
15. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
[TBL] [Abstract][Full Text] [Related]
16. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
17. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
Zarnegar S; Durham BH; Khattar P; Shukla NN; Benayed R; Lacouture ME; Lavi E; Lyden DC; Diamond EL; Dunkel IJ; Abdel-Wahab O
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748614
[TBL] [Abstract][Full Text] [Related]
18. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
